News

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...
The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...
Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...
Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...
Through a trust, Dudum sold about $33.4 million worth of his company’s stock on Thursday, according to a filing with the ...
Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...
HIMS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...
Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...
At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...
Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...